Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib plus methotrexate in rheumatoid arthritis: gut microbiota and efficacy correlation study
ChiCTR2300077468Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Nov 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib and methotrexate in rheumatoid arthritis (RA), sponsored by Beijing Hospital. Primary endpoint: Abundance of gut microbiota. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
tofacitinibmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2300077468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077468.